Wright sees window, albeit narrow one, for US Augment approval
This article was originally published in Clinica
Executive Summary
There may be a light at the end of the tunnel for Wright Medical’s troubled Augment bone graft, after the US FDA agreed to accept a premarket approval (PMA) amendment. The product has looked unlikely to get the go-ahead since last August, when the agency issued a not-approvable letter.